Paper published in a journal (Scientific congresses and symposiums)
Cessation of nucleos(t)ide analogue treatment after HBeAg seroconversion is associated with a 4-fold increased risk of relapse in cirrhotic compared to non-cirrhotic patients
Van Hees, S; Bourgeois, S; Van Vlierberghe, H et al.
2017In Hepatology, 66 (S1), p. 934
Peer Reviewed verified by ORBi
 

Files


Full Text
poster AASLD 2017.pdf
Publisher postprint (89.41 kB)
Download

All documents in ORBi are protected by a user license.

Send to



Details



Disciplines :
Gastroenterology & hepatology
Author, co-author :
Van Hees, S
Bourgeois, S
Van Vlierberghe, H
Sersté, T
Francque, S
Michielsen, P
Sprengers, D
Reynaert, H
Henrion, J
Negrin Dastis, S
DELWAIDE, Jean ;  Centre Hospitalier Universitaire de Liège - CHU > Service de gastroentérologie, hépatologie, onco. digestive
Lasser, L
Decaestecker, J
Orlent, H
Janssens, F
Robaeys, G
Colle, I
Starkel, P
Moreno, C
Nevens, F
Vanwolleghem, T
More authors (11 more) Less
Language :
English
Title :
Cessation of nucleos(t)ide analogue treatment after HBeAg seroconversion is associated with a 4-fold increased risk of relapse in cirrhotic compared to non-cirrhotic patients
Publication date :
October 2017
Event name :
Liver Meeting American Association for the Study of Liver Diseases
Event place :
Washington, United States
Event date :
du 20 octobre 2017 au 24 octobre 2017
Audience :
International
Journal title :
Hepatology
ISSN :
0270-9139
eISSN :
1527-3350
Publisher :
Wiley, Hoboken, United States - New Jersey
Volume :
66
Issue :
S1
Pages :
A934
Peer reviewed :
Peer Reviewed verified by ORBi
Available on ORBi :
since 09 November 2017

Statistics


Number of views
55 (1 by ULiège)
Number of downloads
70 (0 by ULiège)

Bibliography


Similar publications



Sorry the service is unavailable at the moment. Please try again later.
Contact ORBi